Work Packages

Theralymph project’s steps

Therapeutic targets 

$

validation in pre-clinical models

$

Clinical
trial

WP1

Risks factors associated with lymphedema

More Info

(

Lymphatic vessels

'

Adipose tissue

i

WP2

Lymphatic collectors signature in lymphedema

Histology & gene expression

More Info

WP3

Adipocyte dysfunction in lymphedema

Lipolytic activity

More Info

'
(
"

WP4

Resolution of inflamation in lymphedema

Lipid mediators

More Info

"
"
Z

WP5

Validation of therapeutic targets in vitro

Lentivector production, CrispR-ON, CrispR/CAS9, CrispR/CAS13, …

More Info

"
l

WP6

Validation of therapeutic targets in vivo

Lentiflash vector production

More Info

"

WP7

Phase I/II clinical trial for lymphedema

Lentiflash-based gene therapy : recrutment, biodistribution, immune tolerence, doses

More Info

WP8

Coordination & Management

Ethic advisor annual reports

More Info

WP9

Communication, Dissemination and innovation Management

Communications, Theralymph 2024 international meeting

More Info

Theralymph disclaimer

This project has received funding from the European Union’s Horizon 2020 Research & Innovation programme under Grant Agreement no. 874708.

Our website reflects only the authors’ views and the European Union is not liable for any use that may be made of the information contained therein.

Quick Links

Categories

Follow Us

© 2020 Theralymph | Built by © Oreezon